Preventing Chronic Disease | A 16-Month Community-Based Intervention to Increase Aspirin Use for Primary Prevention of Cardiovascular Disease - CDC
A 16-Month Community-Based Intervention to Increase Aspirin Use for Primary Prevention of Cardiovascular Disease
Niki C. Oldenburg, DrPH; Sue Duval, PhD; Russell V. Luepker, MD, MS; John R. Finnegan, PhD; Heather LaMarre, PhD; Kevin A. Peterson, MD; Nicole D. Zantek, MD, PhD; Ginny Jacobs, Med; Robert J. Straka, PharmD; Karen H. Miller, MSW, MPA; Alan T. Hirsch, MD
Suggested citation for this article:
Oldenburg NC, Duval S, Luepker RV, Finnegan JR, LaMarre H, Peterson KA, et al. A 16-Month Community-Based Intervention to Increase Aspirin Use for Primary Prevention of Cardiovascular Disease. Prev Chronic Dis 2014;11:130378. DOI: http://dx.doi.org/10.5888/pcd11.130378
Cardiovascular diseases are the leading causes of disability and death in the United States. Primary prevention of these events may be achieved through aspirin use. The ability of a community-based intervention to increase aspirin use has not been evaluated. The objective of this study was to evaluate an educational intervention implemented to increase aspirin use for primary prevention of cardiovascular disease in a small city in Minnesota.
A community-based intervention was implemented during 16 months in a medium-sized community in Minnesota. Messages for aspirin use were disseminated to individuals, health care professionals, and the general population. Independent cross-sectional samples of residents (men aged 45–79, women aged 55–79) were surveyed by telephone to identify candidates for primary prevention aspirin use, examine their characteristics, and determine regular aspirin use at baseline and after the campaign at 4 months and 16 months.
In primary prevention candidates, regular aspirin use rates increased from 36% at baseline to 54% at 4 months (odds ratio = 2.05; 95% confidence interval, 1.09–3.88); the increase was sustained at 52% at 16 months (odds ratio = 1.89; 95% confidence interval, 1.02–3.49). The difference in aspirin use rates at 4 months and 16 months was not significant (P = .77).
Aspirin use rates for primary prevention remain low. A combined public health and primary care approach can increase and sustain primary prevention aspirin use in a community setting.
Funding was provided by the Lillehei Heart Institute, University of Minnesota Medical School, and in kind contributions from the University of Minnesota School of Public Health. The authors thank the St. Luke’s Clinics–Hibbing Family Medical Clinic, the Essentia Health–Hibbing Clinic, the Fairview Mesaba Clinic–Hibbing, the city and people of Hibbing, Minnesota, and the Minnesota Department of Health for being our partners.
Corresponding Author: Niki C. Oldenburg, DrPH, Vascular Research Project Manager, Cardiovascular Division, University of Minnesota Medical School, MMC 508, 420 Delaware St SE, Minneapolis, MN 55455. Telephone: 612-625-8781. E-mail: email@example.com
Author Affiliations: Sue Duval, Russell V. Luepker, John R. Finnegan, Heather LaMarre, Kevin A. Peterson, Nicole D. Zantek, Ginny Jacobs, Robert J. Straka, Karen H. Miller, Alan T. Hirsch, University of Minnesota, Minneapolis, Minnesota.
- Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics — 2011 update: a report from the American Heart Association. Circulation 2011;123(4):e18–209. CrossRef PubMed
- Farley TA, Dalal MA, Mostashari F, Frieden TR. Deaths preventable in the U.S. by improvements in use of clinical preventive services. Am J Prev Med 2010;38(6):600–9. CrossRef PubMed
- Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989;321(3):129–35. CrossRef PubMed
- Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352(13):1293–304. CrossRef PubMed
- Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT study group. Lancet 1998;351(9118):1755–62. CrossRef PubMed
- Thrombosis prevention trial: randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council’s General Practice Research Framework. Lancet 1998;351(9098):233–41. CrossRef PubMed
- Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295(3):306–13. CrossRef PubMed
- US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2009;150(6):396–404. CrossRef PubMed
- Healthy People 2020 objectives. http://healthypeople.gov/2020/topicsobjectives2020/ebr.aspx?topicid=21. Accessed January 25, 2013.
- Pearson TA, Blair SN, Daniels ST, Eckel RH, Fair JM, Fortmann SP, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002;106(3):388–91. CrossRef PubMed
- Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, et al. ADA/AHA/ACCF scientific statement: aspirin for primary prevention of cardiovascular events in people with diabetes. Circulation 2010;121(24):2694–701. CrossRef PubMed
- Frieden TR, Berwick DM. The “Million Hearts” initiative — preventing heart attacks and strokes. N Engl J Med 2011:365(13):e27. CrossRef PubMed
- Raju N, Sobieraj-Teague M, Hirsh J, O’Donnell M, Eikelboom J. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med 2011;124(7):621–9. CrossRef PubMed
- Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, Sattar N, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012;172(3):209–16. CrossRef PubMed
- Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 2013;159(2):77–85. CrossRef PubMed
- Pignone M, Anderson GK, Binns K, Tilson HH, Weisman SM. Aspirin use among adults aged 40 and older in the United States: results of a national survey. Am J Prev Med 2007;32(5):403–7. CrossRef PubMed
- Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH. Aspirin use among US adults: Behavioral Risk Factor Surveillance System. Am J Prev Med 2006;30(1):74–7. CrossRef PubMed
- VanWormer JJ, Greenlee RT, McBride PE, Peppard PE, Malecki KC, Che J, et al. Aspirin for primary prevention of CVD: are the right people using it? J Fam Pract 2012;61(9):525–32. PubMed
- Sanchez DR, Diez Roux AV, Michos ED, Blumenthal RS, Schreiner PJ, Burke GL, et al. Comparison of the racial/ethnic prevalence of regular aspirin use for the primary prevention of coronary heart disease from the multi-ethnic study of atherosclerosis. Am J Cardiol 2011;107(1):41–6. CrossRefPubMed
- Rodondi N, Vittinghoff E, Cornuz J, Butler J, Ding J, Satterfield S, et al. Aspirin use for the primary prevention of coronary heart disease in older adults. Am J Med 2005;118(11):1288. CrossRef PubMed
- Luepker RV, Steffen LM, Duval S, Zhou X, Hirsch AT. Population trends in aspirin use for cardiovascular disease prevention 1980–2009. Eur Heart J 2013;34(Suppl 1):473.
- Sorensen G, Emmons K, Hunt MK, Johnston D. Implications of the results of community intervention trials. Annu Rev Public Health 1998;19:379–416.CrossRef PubMed
- Papadakis S, Moroz I. Population-level interventions for coronary heart disease prevention: what have we learned since the North Karelia project? Curr Opin Cardiol 2008;23(5):452–61. CrossRef PubMed
- Pennant M, Davenport C, Bayliss S, Greenheld W, Marshall T, Hyde C. Community program for the prevention of cardiovascular disease: a systematic review. Am J Epidemiol 2010;172(5):501–16. CrossRef PubMed
- Ebrahim S, Taylor F, Ward K, Beswick A, Burke M, Davey Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst Rev 2011;(1):CD001561. PubMed
- Community Preventive Services Task Force 2012 annual report to Congress and to agencies related to the work of the task force. http://www.thecommunityguide.org/annualreport/2012-congress-report-full.pdf. Accessed January 25, 2014.
- US Census Bureau. American factfinder community facts: Hibbing, MN. 2010. http://factfinder2.census.gov/faces/nav/jsf/pages/community_facts.xhtml. Accessed September 19, 2013
- Zantek ND, Luepker RV, Duval S, Miller K, Oldenburg N, Hirsch AT. Confirmation of reported aspirin use in community studies: utility of serum thromboxane B2 measurement. Clin Appl Thromb Hemost 2013. CrossRef PubMed
- Strully KW, Fowler JH, Murabito JM, Benjamin EJ, Levy D, Christakis NA. Aspirin use and cardiovascular events in social networks. Soc Sci Med 2012;74(7):1125–9. CrossRef PubMed
- Villablanca AC, Arline S, Lewis J, Raju S, Sanders S, Carrow S. Outcomes of national community organization cardiovascular prevention programs for high-risk women. J Cardiovasc Transl Res 2009;2(3):306–20. CrossRef PubMed
- Eaton CB, Lapane KL, Garber CE, Gans KM, Lasater TM, Carleton RA. Effects of a community-based intervention on physical activity: the Pawtucket Heart Health Program. Am J Public Health 1999;89(11):1741–4. CrossRef PubMed
- Fortmann SP, Flora JA, Winkleby MA, Schooler C, Taylor CB, Farquhar JW. Community intervention trials: reflections on the Stanford Five-City Project. Am J Epidemiol 1995;142(6):576–86. PubMed
- Institute of Medicine. Primary care and public health: exploring integration to improve population health. 2012. http://www.iom.edu/Reports/2012/Primary-Care-and-Public-Health.aspx. Accessed January 25, 2014.
No hay comentarios:
Publicar un comentario